866-997-4948(US-Canada Toll Free)

Myocardial Fibrosis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 85 Pages

Myocardial Fibrosis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Fibrosis - Overview 7
Myocardial Fibrosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Myocardial Fibrosis - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Myocardial Fibrosis - Companies Involved in Therapeutics Development 21
Daewoong Pharmaceutical Co Ltd 21
Evotec AG 21
Galectin Therapeutics Inc 22
Invivosciences Inc 22
Lead Discovery Center GmbH 22
MandalMed Inc 23
Merck & Co Inc 23
Miragen Therapeutics Inc 24
Palatin Technologies Inc 24
ProMetic Life Sciences Inc 25
Sarfez Pharmaceuticals Inc 25
TRACON Pharmaceuticals Inc 26
Myocardial Fibrosis - Drug Profiles 27
BMP-7 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
carotuximab - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Drugs for Tissue Fibrosis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
DWN-10290 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
GRMD-02 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
MRG-201 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
NM-922 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PBI-4050 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
PL-5028 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PN1-Ab - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
SP-20102 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
TPI-2049 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
TRC-205 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
VB-0004 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Myocardial Fibrosis - Dormant Projects 81
Myocardial Fibrosis - Product Development Milestones 82
Featured News & Press Releases 82
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 82
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables
Number of Products under Development for Myocardial Fibrosis, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products under Development by Universities/Institutes, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Universities/Institutes, H2 2017 12
Number of Products by Stage and Target, H2 2017 14
Number of Products by Stage and Mechanism of Action, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 21
Myocardial Fibrosis - Pipeline by Evotec AG, H2 2017 22
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017 22
Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2017 22
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2017 23
Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2017 23
Myocardial Fibrosis - Pipeline by Merck & Co Inc, H2 2017 24
Myocardial Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2017 24
Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 26
Myocardial Fibrosis - Dormant Projects, H2 2017 81

List of Figures
Number of Products under Development for Myocardial Fibrosis, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products by Top 10 Targets, H2 2017 13
Number of Products by Stage and Top 10 Targets, H2 2017 13
Number of Products by Top 10 Mechanism of Actions, H2 2017 15
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 15
Number of Products by Routes of Administration, H2 2017 17
Number of Products by Stage and Routes of Administration, H2 2017 17
Number of Products by Molecule Types, H2 2017 19
Number of Products by Stage and Molecule Types, H2 2017 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *